Literature DB >> 9661204

An efficient route to human bispecific IgG.

A M Merchant1, Z Zhu, J Q Yuan, A Goddard, C W Adams, L G Presta, P Carter.   

Abstract

Production of bispecific IgG (BsIgG) by coexpressing two different antibodies is inefficient due to unwanted pairings of the component heavy and light chains. To overcome this problem, heavy chains were remodeled for heterodimerization using engineered disulfide bonds in combination with previously identified "knobs-into-holes" mutations. One of the variants, S354C:T366W/Y349'C:T366'S:L368'A:Y407++ +'V, gave near quantitative (approximately 95%) heterodimerization. Light chain mispairing was circumvented by using an identical light chain for each arm of the BsIgG. Antibodies with identical light chains that bind to different antigens were identified from an scFv phage library with a very restricted light chain repertoire for the majority (50/55) of antigen pairs tested. A BsIgG capable of simultaneously binding to the human receptors HER3 and cMpI was prepared by coexpressing the common light chain and corresponding remodeled heavy chains followed by protein A chromatography. The engineered heavy chains retain their ability to support antibody-dependent cell-mediated cytotoxicity as demonstrated with an anti-HER2 antibody.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661204     DOI: 10.1038/nbt0798-677

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  146 in total

1.  Sequencing a Bispecific Antibody by Controlling Chain Concentration Effects When Using an Immobilized Nonspecific Protease.

Authors:  Robert A D'Ippolito; Maria C Panepinto; Keira E Mahoney; Dina L Bai; Jeffrey Shabanowitz; Donald F Hunt
Journal:  Anal Chem       Date:  2020-07-13       Impact factor: 6.986

Review 2.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

Review 3.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

4.  Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.

Authors:  Alexander K Haas; Christoffer von Schwerin; Daniela Matscheko; Ulrich Brinkmann
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

5.  Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Authors:  Kannan Gunasekaran; Martin Pentony; Min Shen; Logan Garrett; Carla Forte; Anne Woodward; Soo Bin Ng; Teresa Born; Marc Retter; Kathy Manchulenko; Heather Sweet; Ian N Foltz; Michael Wittekind; Wei Yan
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

6.  Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Authors:  Christoph Spiess; Jack Bevers; Janet Jackman; Nancy Chiang; Gerald Nakamura; Michael Dillon; Hongbin Liu; Patricia Molina; J Michael Elliott; Whitney Shatz; Justin M Scheer; Glen Giese; Josefine Persson; Yin Zhang; Mark S Dennis; James Giulianotti; Prateek Gupta; Dorothea Reilly; Enzo Palma; Jianyong Wang; Eric Stefanich; Heleen Scheerens; Germaine Fuh; Lawren C Wu
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

Review 7.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 8.  Ligand-targeted delivery of therapeutic siRNA.

Authors:  Yutaka Ikeda; Kazunari Taira
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 9.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

Review 10.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.